Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML

R K Malladi, A J Peniket, T J Littlewood, K E Towlson, R Pearce, J Yin, J D Cavenagh, Charles Craddock, K H Orchard, E Olavarria, G McQuaker, M Collin, D I Marks, British Society of Blood and Marrow Transplantation

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)

Abstract

By retrospective analysis of 88 patients from the British Society of Blood and Marrow Transplantation registry, we investigated the effect of in vivo T-cell depletion in HLA-identical sibling reduced-intensity conditioning (RIC) allografts for adult AML by comparing patients who received alemtuzumab with those without alemtuzumab conditioning. Both groups were equivalent for age, sex, karyotype and disease status at transplant. With a median follow-up of 27 months (3-72 months) and 48 months (7-72 months), the 2- and 5-year overall survival, with or without alemtuzumab, is 60 and 60% (P=0.80) and 61 and 53%, respectively (P=0.85). The 2-year non-relapse mortality is 12% with alemtuzumab, and 17% without alemtuzumab (P=0.49). The 2-year relapse rate is 35% with alemtuzumab compared with 19% without alemtuzumab (P=0.28). Grades II-IV acute GVHD occurred in 22% (8/37) without alemtuzumab compared with 14% (7/51) given alemtuzumab (P=0.25). Extensive chronic GVHD occurred in 47% (14/30) not given alemtuzumab compared with 4% (2/45) who were given alemtuzumab (P=0.001). Among evaluable patients, the risk of infections was higher in those treated with alemtuzumab compared with those not treated with alemtuzumab (79 vs 57%, respectively, P=0.02). In conclusion, alemtuzumab has a beneficial effect by reducing chronic GVHD without affecting overall survival. Further studies are warranted before alemtuzumab can be recommended as standard in RIC allografts for AML.
Original languageEnglish
Pages (from-to)709-15
Number of pages7
JournalBone Marrow Transplantation
Volume43
Issue number9
Early online date24 Nov 2008
DOIs
Publication statusPublished - May 2009

Keywords

  • Young Adult
  • Antibodies, Neoplasm
  • Transplantation Conditioning
  • Antineoplastic Agents
  • Humans
  • Retrospective Studies
  • Aged
  • Transplantation, Homologous
  • Leukemia, Myeloid, Acute
  • Registries
  • Antibodies, Monoclonal
  • Drug Evaluation
  • Survival Rate
  • Lymphocyte Depletion
  • Adult
  • Hematopoietic Stem Cell Transplantation
  • Graft vs Host Disease
  • Siblings
  • Middle Aged
  • Chronic Disease
  • Adolescent
  • Antibodies, Monoclonal, Humanized
  • Female

Fingerprint

Dive into the research topics of 'Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML'. Together they form a unique fingerprint.

Cite this